Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
about
sameAs
Clozapine: a review of clinical practice guidelines and prescribing trendsClozapine augmentation for treatment-resistant schizoaffective disorderPerphenazine for schizophreniaPharmacological interventions for clozapine-induced sinus tachycardiaQuetiapine versus other atypical antipsychotics for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaClozapine versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature reviewPharmacologic treatment of schizophreniaSubstance abuse and schizophrenia: pharmacotherapeutic interventionIncreasing off-label use of antipsychotic medications in the United States, 1995-2008Current perspectives in the treatment of resistant schizophreniaA roadmap to key pharmacologic principles in using antipsychoticsPharmacological interventions for clozapine-induced sinus tachycardiaThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and functionRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesComorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates TreatmentClozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical reviewPimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disordersA genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug targetAntipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyResults of phase 3 of the CATIE schizophrenia trial.The evolution of drug development in schizophrenia: past issues and future opportunities.An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsComparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IIPatterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.Predictors of switching antipsychotic medications in the treatment of schizophreniaPotential role of patients' CYP3A-status in clozapine pharmacokinetics.
P2860
Q21260307-8039C9E6-B67F-451F-A77A-BA25F5322731Q24186084-46118FC4-824D-49F4-8F8E-422E58280DE5Q24187359-C23B3821-3FA3-4158-A815-4C36657465CEQ24187704-E8BF7668-3F58-4CAA-9E80-D5E9202C8FADQ24202427-E0ACBFC4-65ED-4B8E-8734-C382B161D4C2Q24234950-7DCEEBCC-8F7D-48CE-8A03-569D127735A9Q24236422-C05F3A9C-2BEB-4F99-9095-2B478F1ACE75Q24236545-26A3E793-34BF-4AA0-BF1E-EA3AAC7C85A8Q24240989-FB2B0E39-DF8F-4313-98B2-A4F2F7EEF43DQ24598636-382DB717-CCBA-4C49-8BAC-50ABFFEB9229Q24604457-51E765B8-61A1-427E-9A45-AA7D41D816A7Q24621711-61B1C957-C6AC-4C5E-BAB6-164F25F04852Q24628874-2D06BAF6-66E5-4B72-9845-823CD541C7CFQ24628874-6EFF9070-9861-4E57-A98E-4C13FF2BC854Q24650594-0A2E4AF8-42F9-4AF4-9251-639F8D94EB70Q24678461-9A3388EB-45F0-4558-BAC2-64FC72F64DEFQ26471506-1694A294-C4F8-4B56-9E70-A0AD58F61A5EQ26821785-0A4C405C-64E0-4C57-B634-E6392700067BQ26863435-BD4E3F7B-07EB-4DC4-8FE5-341450780A3CQ27015872-32B619EE-3260-4407-B9A6-4133F857A936Q27015872-468F4341-0033-4D8A-9C52-AE0D75F403DFQ28274106-3AB9B085-D384-4E58-80DD-B71397C24A65Q28302151-FBBD9972-BCB8-472E-A270-0A1C82810E26Q28487183-188B221D-0DE8-4412-A157-EF0223E3446FQ30370326-45105407-A73A-4478-A06A-A9E9B8AE666FQ30383064-75203BF5-C6CB-4AD0-8B7F-D37A5EFCD7ADQ30383064-CAF3B634-0F02-498C-9C2F-0A548B4C8787Q30387361-7F4F3731-0E1B-441E-B008-AE15AC7F6017Q30421478-A0B701FD-FE09-4E32-9412-8312060BAABBQ30485065-7A9B9B0D-6016-4A6B-8DD4-12A00C9EFFDEQ30487308-8EA1A144-90DF-4D2A-AB1E-D3102B4D039FQ30487850-4514D570-344B-4D28-A4EB-10AA897A547EQ30487850-6AC04AED-91F5-4CB8-B99E-B5847A415DB4Q30491026-29FE307D-3CAC-4199-B7E3-B7AC2DC90917Q30882594-B6EE60E3-3C38-4C2C-9242-DCF56B7CABC9Q31115350-A1E7861F-F82F-4399-A00E-B038A3F4B1CDQ33160283-6492A4B5-B794-48C2-84FA-9FC6B0EC0B76Q33488323-381DB225-24CE-43DC-8D6E-315DFD0BE050Q33566124-3BDE764A-DEBD-4810-BF4E-8EF4740ED820Q33566124-E7272CD0-1240-47D5-B637-CE3DF5E7F56C
P2860
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@ast
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@en
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@nl
type
label
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@ast
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@en
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@nl
altLabel
Effectiveness of Clozapine Ver ...... ypical Antipsychotic Treatment
@en
Effectiveness of Clozapine Ver ...... ypical Antipsychotic Treatment
@nl
prefLabel
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@ast
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@en
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@nl
P2093
P1476
Effectiveness of Clozapine Ver ...... ypical Antipsychotic Treatment
@en
Effectiveness of clozapine ver ...... pical antipsychotic treatment.
@en
P2093
CATIE Investigators
Clarence E Davis
Diana O Perkins
Herbert Y Meltzer
Jeffrey A Lieberman
Joanne Severe
John K Hsiao
Joseph McEvoy
Joseph P McEvoy
Marvin S Swartz
P356
10.1176/AJP.2006.163.4.600
10.1176/APPI.AJP.163.4.600
P407
P577
2006-04-01T00:00:00Z